Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:44 PM
Ignite Modification Date:
2025-12-24 @ 11:44 PM
NCT ID:
NCT01774851
Eligibility Criteria:
Inclusion Criteria:
* Patients must have documentation of histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or stomach
* Patients must have documentation of histologically or cytologically confirmed HER2 expression
* Patients must be ≥18 years of age
* Patients must have ECOG PS of 0, 1, or 2
* Patients must have adequate hematologic status, renal and hepatic function
Exclusion Criteria:
* Patients with known hypersensitivity to any of the components of MM-111
* Patients with a known history of hypersensitivity to paclitaxel or other drugs formulated in Cremophor® EL
* Patients with a known history of hypersensitivity to trastuzumab or any of its components (group 1 patients only)
* Patients with an active infection or with an unexplained fever \>38.5°C
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01774851
Study Brief:
Protocol Section:
NCT01774851